[
    {
        "content": "* Abiomed announces Q2 fy 2018 revenue of $132.8 million  up 29% and record u.s. Patient utilization  up 33 pct",
        "date": "10262017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Q2 earnings per share $0.54 "
    },
    {
        "content": "JERUSALEM  Sept 28 Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc   a maker of catheter-based heart pumps  and venture capital firm Pitango.",
        "date": "09282017",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "Abiomed invests in Israeli medical device maker Magenta "
    },
    {
        "content": "* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:",
        "date": "09202017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure "
    },
    {
        "content": "* Says \u200dis maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing\u200b",
        "date": "08282017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed maintains fiscal year 2018 revenue guidance "
    },
    {
        "content": "* ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant",
        "date": "08282017",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-ABIOMED says CFO Michael Tomsicek resigns "
    },
    {
        "content": "* Abiomed announces Q1 FY 2018 revenue of $132.5 million  up 29% over prior year",
        "date": "07272017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Q1 gaap earnings per share $0.82 "
    },
    {
        "content": "* Abiomed announces Q1 FY 2018 revenue of $132.5 million  up 29 pct over prior year",
        "date": "07272017",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed reports Q1 EPS $0.82 "
    },
    {
        "content": "* New study with Abiomed's Impella 2.5\u00ae heart pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery Source text for Eikon: Further company coverage:",
        "date": "06302017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-New study with Abiomed's Impella 2.5 Heart Pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery "
    },
    {
        "content": "* Abiomed - enrollment of first patient in fda approved prospective feasibility study  STEMI door to unloading with Impella CP system in acute myocardial infarction",
        "date": "05042017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed says enrolled first patient in FDA approved prospective feasibility study "
    },
    {
        "content": "* Abiomed announces Q4 fy 2017 revenue of $124.7 million  up 33% over prior year and total year revenue of $445.3 million  up 35% over prior year",
        "date": "05042017",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Q4 gaap earnings per share $0.33 "
    },
    {
        "content": "* Abiomed announces q4 fy 2017 revenue of $124.7 million  up 33% over prior year and total year revenue of $445.3 million  up 35% over prior year",
        "date": "05042017",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed announces Q4 revenue of $124.7 million  up 33 pct "
    },
    {
        "content": "* Abiomed announces Q3 FY 2017 revenue of $114.7 million  up 34% over prior year",
        "date": "01262017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Q3 GAAP earnings per share $0.34 "
    },
    {
        "content": "* Says increasing lower end of its fiscal year 2017 revenue guidance with new range of $440 million to $445 million",
        "date": "01262017",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Q3 earnings per share $0.34 "
    },
    {
        "content": "* Abiomed announces preliminary q3 fy 2017 revenue of $114.7 million  up 34% over prior year",
        "date": "01092017",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed announces preliminary q3 preliminary revenue "
    },
    {
        "content": "* Abiomed announces q2 fy 2017 revenue of $103 million  up 35% over prior year",
        "date": "10272016",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Q2 revenue of $103 million  up 35 pct over prior year "
    },
    {
        "content": "* Abiomed receives fda ide approval for initiation of door to unloading (dtu) prospective feasibility study",
        "date": "10272016",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed receives FDA ide approval for initiation of door to unloading prospective feasibility study "
    },
    {
        "content": "* Receives FDA IDE approval for initiation of door to unloading (DTU) prospective feasibility study",
        "date": "10272016",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed receives FDA IDE approval for initiation of DTU prospective feasibility study "
    },
    {
        "content": "* Announces Q2 FY 2017 revenue of $103 million  up 35% over prior year",
        "date": "10272016",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed reports Q2 FY 2017 gaap earnings per share $0.20 "
    },
    {
        "content": "* Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health  Labor & Welfare",
        "date": "09272016",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health  Labor & Welfare "
    },
    {
        "content": "* Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20%",
        "date": "07282016",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed reports Q1 gaap earnings per share of $0.29 "
    },
    {
        "content": "* Abiomed announces Q4 FY 2016 revenue of $94.0 million  up 39% over prior year",
        "date": "05032016",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed reports Q4 GAAP earnings per share $0.24 "
    },
    {
        "content": "* Abiomed announces Q4 FY 2016 revenue of $94.0 million  up 39 pct over prior year",
        "date": "05032016",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed posts Q4 earnings per share $0.24 "
    },
    {
        "content": "April 7 The U.S Food and Drug Administration approved Abiomed Inc's heart pump to treat patients who suffer cardiac shock after heart attack or heart surgery  sending its shares up about 4 percent in extended trading.",
        "date": "04072016",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "FDA approves Abiomed's device to treat cardiac shocks "
    },
    {
        "content": "* Abiomed impella therapy receives fda approval for cardiogenic shock after heart attack or heart surgery",
        "date": "04072016",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed Impella therapy receives FDA approval "
    },
    {
        "content": "* Co  FDA agreed on indication for use for pre-market approval ('PMA') for Impella 2.5  Impella CP  Impella 5.0 and Impella LD devices",
        "date": "03212016",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "BRIEF-Abiomed does not anticipate FDA advisory panel prior to PMA approval "
    },
    {
        "content": "The U.S. Food and Drug Administration said it approved Abiomed Inc's miniature blood pump system that maintains heart function and circulation during high-risk procedures.",
        "date": "03232015",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "FDA approves Abiomed's blood pump device "
    },
    {
        "content": "March 23 The U.S. Food and Drug Administration said it approved Abiomed Inc's miniature blood pump system that maintains heart function and circulation during high-risk procedures.",
        "date": "03232015",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "UPDATE 1-FDA approves Abiomed's blood pump device "
    },
    {
        "content": "A federal appeals court has thrown out a lawsuit accusing Abiomed Inc of deceiving shareholders about how it marketed its flagship heart pump  and said companies should be encouraged to deal with regulators without having to fear that such dealings could lead to securities fraud claims.",
        "date": "02102015",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "Abiomed beats fraud lawsuit as court encourages regulatory dealings "
    },
    {
        "content": "Medical device maker Abiomed Inc  raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump  sending its stock up about 30 percent in extended trading.",
        "date": "01282015",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "Abiomed raises revenue outlook  wins US approval for heart pump "
    },
    {
        "content": "Medical device maker Abiomed Inc  raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump  sending its stock nearly 32 percent in extended trading.",
        "date": "01272015",
        "name": "ABIOMED Inc",
        "news_type": "topStory",
        "symbol": "ABMD",
        "title": "Abiomed raises revenue outlook  wins U.S. approval for heart pump "
    },
    {
        "content": "Jan 27 Medical device maker Abiomed Inc  raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump  sending its stock up about 30 percent in extended trading.",
        "date": "01282015",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "UPDATE 2-Abiomed raises revenue outlook  wins US approval for heart pump "
    },
    {
        "content": "Jan 27 Medical device maker Abiomed Inc  raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump  sending its stock nearly 32 percent in extended trading.",
        "date": "01282015",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "CORRECTED-UPDATE 1-Abiomed raises revenue outlook  wins US approval for heart pump "
    },
    {
        "content": "Jan 27 Medical device maker Abiomed Inc  raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump  sending its stock nearly 32 percent in extended trading.",
        "date": "01272015",
        "name": "ABIOMED Inc",
        "news_type": "normal",
        "symbol": "ABMD",
        "title": "UPDATE 1-Abiomed raises revenue outlook  wins US approval for heart pump "
    }
]